about
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomasThe risks of overlooking the diagnosis of secreting pituitary adenomasManaging Prolactinomas during PregnancyCabergoline associated with first episode maniaDemographic differences in incidence for pituitary adenoma.What can we learn from rodents about prolactin in humans?An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and proteinCharacteristics of dynamic magnetic resonance image enhancement in prolactinomas resistant to dopamine agonist therapy.Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma.Geographic-Related Differences of Pituitary Adenomas Hormone Profile: Analysis of Two Groups Coming from Southeastern and Eastern EuropeThrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1).Effect of dopaminergic drug treatment on surgical findings in prolactinomas.Giant Prolactinoma Presenting with Neck Pain and Structural Compromise of the Occipital Condyles.Imaging of pediatric pituitary endocrinopathiesDevelopmental and Functional Effects of Steroid Hormones on the Neuroendocrine Axis and Spinal CordPituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood.Angiogenesis and pituitary tumors.Resistant prolactinomas.Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas.Macroprolactinoma: a diagnostic and therapeutic update.Giant prolactinomas: the therapeutic approach.Gene expression in prolactinomas: a systematic review.Factors related to recurrence of idiopathic granulomatous mastitis: what do we learn from a multicentre study?Pediatric Suprasellar Tumors.The safety of treatments for prolactinomas.Hyperprolactinemia: An often missed cause of male infertility.The epidemiology of pituitary adenomas in a community-based hospital: a retrospective single center study in Saudi Arabia.Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases.Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.[Hyperprolactinemia: unusual association between peripheral hypothyroidism and microprolactinoma].Absence of an opioid stimulatory tone on growth hormone secretion in women with microprolactinoma.Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.Males with prolactinoma are at increased risk of incident cardiovascular disease.Long-term outcome of multimodal therapy for giant prolactinomas.Surgical treatment of prolactinomas: cons.Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
P2860
Q26772167-042D115A-359A-4DC0-9096-4B01884B7F27Q28076665-26B3C1B7-D3F6-4898-87F5-E9D7B470E902Q28080990-DD915B83-214E-48E6-AA4F-FC854CB61BE8Q33901882-16258AB8-CC41-4AAE-92AD-29590261D33FQ34135358-3E46F025-FB5F-421B-ACBC-57B5C5FDB47FQ34721567-13C0A8B1-35CE-4AC2-B39A-BEDA298E5AC8Q35072652-5AAEFA30-E0C7-40DC-8DBB-2632D93AAAE5Q35106933-A534360E-56B8-4756-BDB4-B9C814A64A77Q35493390-F94EF8C4-7B80-4B42-906B-417F4E901D24Q35640741-678EBA58-821E-4477-910A-6495B67EE661Q36113958-1A1E6EBC-7994-4741-9D21-BE7ADA1AE5B5Q36182003-DC8A50ED-E8F3-4FDF-A7DD-A0FBBB6CA90FQ36289364-D8525A87-231A-4925-BD7A-50C5C83EA0B9Q36331597-7F0B6C22-2F4F-4E2C-B7DC-0AC4E4FE515FQ37116064-F81AB249-45CC-42B0-84B0-7937AF07EF5DQ37139774-B40235B1-0EAE-4C15-A253-23900D391CE8Q37425200-76FAF34A-EBDC-4443-AD58-36B5E2F50317Q37479382-6848CE37-86DF-4B36-8D7A-AA4B47E3A513Q37853323-A4237B56-BAEB-45C3-81B8-5E4829F8AF41Q38028958-D69B5B7B-2698-4780-B89E-605E205D887EQ38074909-E9CD661A-461E-492F-A719-812F7D819D25Q38105620-CDF04E92-A042-44B3-A279-995D6D8F22B5Q38559883-1B17B7CF-1EE4-4AA2-99B6-39EAAAE94123Q38658122-E38CB831-12CB-4EED-B7C6-4D556C450832Q38671531-16D8E4BC-10A6-47E8-B268-352F4775EB27Q38726058-28DD7028-6010-4DA2-A5C1-2B29A199E2AEQ38893540-2170311F-82CF-4164-BB17-60D17E1DEE08Q39316697-0ED712B6-C0E1-4D63-9194-3D4BBA2F1D15Q39925726-E1EDA052-ADEC-4EB5-8F2A-CF997E92DB2DQ40730569-7BAB4DD1-1CC4-4C70-B4A6-5D699188A596Q41024285-58C8255A-74E5-42DA-A065-54C0C0A19BF1Q44341276-A61A86F3-57FB-4DC4-87C0-B44E8812B21DQ44960679-B841BA19-BF62-4854-8B06-4B12FEFB6F70Q47266565-CC9562B8-8261-48E1-91D6-2D569080742FQ47425359-60B8504A-720E-49E7-984A-CA77333D778FQ47606133-14579271-1278-4995-9D46-E3BD8B62FDF9Q47669109-4BB0A7C4-5B44-4577-B02E-85BD2680FB73Q47833165-12ACB98C-F38F-4B50-9FF5-493C8F4465DFQ49125108-13EDD949-FF38-48E0-8CAF-4DAF5DFDF5FAQ49717139-E7E46BB3-CDCC-476F-A0E1-8B07ECE3D727
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The epidemiology of prolactinomas.
@en
The epidemiology of prolactinomas.
@nl
type
label
The epidemiology of prolactinomas.
@en
The epidemiology of prolactinomas.
@nl
prefLabel
The epidemiology of prolactinomas.
@en
The epidemiology of prolactinomas.
@nl
P2860
P1433
P1476
The epidemiology of prolactinomas.
@en
P2093
Albert Beckers
Antonio Ciccarelli
P2860
P2888
P356
10.1007/S11102-005-5079-0
P577
2005-01-01T00:00:00Z